Emanuel Petricoin III, co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University discusses proteomics research, which may help predict a patient's prognosis or response to therapy: "Our vision is to truly personalize therapy by providing key, missing information to the physician about the state of their patients' cellular circuitry, which contains the drug targets."